Clinical standard research of multicenter clinical control study of noncytotoxic drug- gastric carcinoma D2 radical correction- Capecitabine combined therapy in gastric carcinoma.
Phase of Trial: Phase IV
Latest Information Update: 21 May 2012
At a glance
- Drugs Capecitabine (Primary) ; Celecoxib; Lanreotide
- Indications Gastric cancer
- Focus Therapeutic Use
- 21 May 2012 Planned end date 31 May 2013 added as reported by Chinese Clinical Trial Register.
- 14 Nov 2011 New trial record